Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-25-Q-9304

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), acting on behalf of the Department of Defense (DoD), has issued a solicitation (Procurement Identifier: HT9402-25-Q-9304) seeking quotations from qualified pharmaceutical manufacturers for participation in the DoD Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is a critical component of the DoD’s statutory mandate under 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21) to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The primary objective of this solicitation is to secure competitive pricing and establish agreements for pharmaceutical agents that are under consideration for placement on the DoD Uniform Formulary (UF). The UF is a carefully curated list of medications, selected based on clinical effectiveness and cost efficiency, to ensure optimal therapeutic outcomes and value for the MHS beneficiary population. The process is overseen by the DoD Pharmacy and Therapeutics (P&T) Committee, which evaluates drugs within specific therapeutic classes and makes recommendations regarding their formulary status—such as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). For the August 2025 P&T Committee meeting, the following newly approved drugs will be reviewed for potential inclusion in the UF: - Andembry (Corticosteroids-Immune Modulators-Hereditary Angioedema Agents) - Arbli (Renin-Angiotensin Antihypertensives - Angiotensin II Receptor Blockers) - Avmapki Fakzynja Co-pack (Oncological Agents) - Ensacove (Oncological Agents) - Ibtrozi (Oncological Agents) - Imuldosa (Targeted Immunomodulatory Biologics - IL-23) - Khindivi (Corticosteroids-Immune Modulators) - Merilog (Insulins - Rapid-Acting Agents) - nilotinib tartrate (Oncological Agents - Chronic Myelogenous Leukemia) - Tryptyr (Ophthalmic - Dry Eye) - ustekinumab-aekn (Targeted Immunomodulatory Biologics - IL-23) - Yutrepia (Pulmonary Arterial Hypertension - Prostacyclin Nebulized) - Zelsuvmi (Antiinfectives - Miscellaneous) The solicitation includes detailed instructions, deadlines, and points of contact, all of which are outlined in the attached RFQ document (HT9402-25-Q-9304) and its appendices. Contractors are advised to review these documents thoroughly to understand the submission requirements and evaluation criteria. A pre-quotation teleconference is scheduled for July 16, 2025, as detailed in Part 2.4 of the RFQ, providing an opportunity for interested parties to seek clarification and guidance. Responses to clinical questions (Part 3.4) must be submitted via email to the designated point of contact by the deadline specified in Part 2.3.2. This procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). There are no set-aside restrictions; the opportunity is open to all qualified entities. The place of performance is San Antonio, Texas, United States. The contracting entity for this solicitation is the Defense Health Agency, a federal office responsible for managing the MHS pharmacy benefits program. The primary point of contact is Tracy Banks ([email protected]), with Stephanie Erpelding ([email protected]) as the secondary contact. Interested contractors should note the following key dates: - Pre-quotation teleconference: July 16, 2025 - Quotation submission deadline: July 30, 2025, 17:07 This solicitation represents a significant opportunity for pharmaceutical manufacturers to partner with the DoD in delivering high-quality, cost-effective medications to military beneficiaries. Contractors are encouraged to review the full solicitation and associated attachments, available at https://sam.gov/opp/3e3759ac9aa44a179ebf2a4697597ee5/view, to determine alignment with their product portfolios and capabilities. The requirements and objectives outlined in this notice are expected to remain consistent throughout the contract lifecycle, focusing on the provision of clinically effective and economically advantageous pharmaceutical agents for the DoD Uniform Formulary.
Documents31